Eli Lilly) became the first oral GLP-1 with no food, water, or timing restrictions for chronic weight management, approved April 1, 2026
Clinical Trial Evidence for Wegovy Wegovy approval was supported by large, randomized clinical trials, including the STEP 1 study: 1,961 adults with obesity or overweight plus weight-related health conditions 68-week study duration Average weight loss of approximately 14.9% of body weight 86% of participants lost at least 5% of body weight 69% lost at least 10% 50% lost at least 15% Participants followed reduced-calorie diets and increased physical activity Before receiving FDA approval, GLP-1 medications completed Phase I, Phase II, and Phase III trials
Injection timing optimization Choosing the best time of day for your injection can influence side effect severity
Because of the reduction in testosterone, men should not use spironolactone as an acne treatment
If you have telogen effluvium, they may pull at least four to six hairs from your scalp with white bulbs at the roots
